Real-World study reveals why MS patients switch to ozanimod
NCT ID NCT05658601
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their current medication to ozanimod. Researchers wanted to understand the reasons for the switch—such as lack of effectiveness, side effects, or patient preference—and how the switch was managed. The study did not test a new treatment but observed real-world use to gather information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Isernia, 86077, Italy
Conditions
Explore the condition pages connected to this study.